MedPath

A study to determine the effect of post-infusion cooling time in the high dose 5-fluorouracil, 4-epidoxorubicin and cyclophosphamide (FEC)-regime

Completed
Conditions
Cancer
Breast cancer, hair loss
Registration Number
ISRCTN97879847
Lead Sponsor
Medical Centre Alkmaar (Medisch Centrum Alkmaar) (The Netherlands)
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Completed
Sex
Female
Target Recruitment
130
Inclusion Criteria

1. Intravenously administered FEC-regimen with an epirubicin dose of 90 mg/m^2 or more at three-weekly intervals
2. Aged 18 years or more
3. Written informed consent

Exclusion Criteria

1. Baldness before the start of the study
2. Hematological malignancies with generalized haematogenic metastases and if in those conditions chemotherapy is given with a curative intent
3. Clinical signs of scalp metastases

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Amount of hair loss
Secondary Outcome Measures
NameTimeMethod
1. Acceptability of scalp cooling<br>2. Relation of the efficacy of scalp cooling with prior chemotherapy, radiotherapy or hormonal treatment, liver or kidney function disorder and type of hair<br>3. Quality of life during chemotherapy
© Copyright 2025. All Rights Reserved by MedPath